Clinical Research Directory
Browse clinical research sites, groups, and studies.
Staccato Prochlorperazine Single Dose PK Study
Sponsor: Nova Pneuma Inc.
Summary
The objective of this study was to evaluate the tolerability, safety, and pharmacokinetics of inhaled prochlorperazine
Official title: Tolerability, Safety and Pharmacokinetics of a Single Dose of Staccato™ Prochlorperazine for Inhalation in Normal, Healthy Volunteers
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
54
Start Date
2004-08
Completion Date
2004-10
Last Updated
2026-04-22
Healthy Volunteers
Yes
Conditions
Interventions
Prochlorperazine 0.5 mg IV over 5 sec
IV Prochlorperazine for bioavailability
Inhaled prochlorperazine 0.625 mg
Inhaled Staccato Prochlorperazine 0.625 mg
Inhaled prochlorperazine 1.25 mg
Inhaled Staccato Prochlorperazine 1.25 mg
Inhaled prochlorperazine 2.5 mg
Inhaled Staccato Prochlorperazine 2.5 mg
Inhaled prochlorperazine 5 mg
InhaledStaccato Prochlorperazine 5 mg
Inhaled prochlorperazine 10 mg
InhaledStaccato Prochlorperazine 10 mg
Inhaled placebo
Inhaled Staccato Placebo (0 mg)
Prochlorperazine 10 mg IV over 5 sec
Prochlorperazine 10 mg IV over 5 sec for patient qualification
Locations (1)
PPD Phase I Clinic
Austin, Texas, United States